Clinical Trial Update: Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating nimotuzumab plus irinotecan as second-line therapy for recurrent or metastatic gastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Stomach Neoplasms

Drugs mentioned

• Irinotecan (Irinotecan)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Peking University | Conditions: Stomach Neoplasms | Phase 2 | Status: UNKNOWN